Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06976203 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

A Phase 3 study of Alzheimers Disease, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 3
Development phase
586
Enrollment target
20
Study locations

NCT06976203 is a Phase 3 study of Alzheimers Disease that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 586 participants, below the 4,057-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06976203, a Phase 3 study of Alzheimers Disease, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 3
Development phase
586 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

Conditions Studied

Alzheimers Disease

Interventions

  • OTHER Placebo
  • DRUG KarXT
  • DRUG KarX-EC

Study Locations (20)

Florida

  • Neuropsychiatric Research Center of Southwest Florida - Fort Myers
  • Velocity Clinical Research, Hallandale Beach - Hallandale
  • Jacksonville Center for Clinical Research - Jacksonville
  • K2 MEDICAL Research THE VILLAGES - Lady Lake
  • Intercoastal Medical Group - Sarasota
  • USF Health Byrd Alzheimer's Institute - Tampa
  • Alzheimer's Research and Treatment Center - Wellington

California

  • Fullerton Neurology and Headache Center - Fullerton
  • Inglewood Clinical - Inglewood
  • Irvine Clinical Research - Irvine
  • Local Institution - 0083 - Palo Alto
  • Local Institution - 0069 - San Diego

Illinois

  • Great Lakes Clinical Trials - Andersonville - Chicago
  • Southern Illinois University School of Medicine - Springfield

Colorado

  • Research of the Rockies - Colorado Springs

Indiana

  • Josephson Wallack Munshower Neurology, PC - Indianapolis

Massachusetts

  • Local Institution - 0080 - Watertown

Michigan

  • QUEST Research Institute - Farmington Hills

Mississippi

  • Private Practice - Dr. Ronald Louis Schwartz - Hattiesburg

Trial Details

FieldValue
Enrollment Target 586 participants
Start Date 2025-07-21
Est. Completion 2029-02-23
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06976203

The ClinicalTrials.gov registry entry for NCT06976203 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 586 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,057-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (86% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06976203 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT06976203 about?

NCT06976203 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)". The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

What is the current status of trial NCT06976203?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 586 participants. The study started on 2025-07-21. Estimated completion is 2029-02-23.

What conditions does trial NCT06976203 study?

This clinical trial studies the following conditions: Alzheimers Disease.

What interventions are being tested in trial NCT06976203?

The interventions under investigation include: Placebo (OTHER), KarXT (DRUG), KarX-EC (DRUG).

Who is sponsoring clinical trial NCT06976203?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06976203 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimers Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimers Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.